2023
DOI: 10.1155/2023/1691996
|View full text |Cite
|
Sign up to set email alerts
|

Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient

Kim Abbegail Tan Aldecoa,
Chef Stan L. Macaraeg,
Akash Dadlani
et al.

Abstract: Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-old patient with a known diagnosis of CLL on ibrutinib treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 12 publications
0
0
0
Order By: Relevance